Bioprogress General Discussion

This never really came to anything did it?


Bioprogress Custom Pharmaceuticals Ltd


RNS Number:4344I
BioProgress PLC
10 February 2005


Press Release 10 February 2005




BioProgress plc
("BioProgress" or "the Company")

BioProgress signs contract with Custom Pharmaceuticals for new UK
pharmaceutical film manufacturing facility and appoints Callisto Consulting to

progress US and European medicines product license applications



BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery
mechanisms for the pharmaceutical oral dosage markets, announces that it has now
executed an agreement with Custom Pharmaceuticals Limited ("Custom") to install
a film manufacturing line in Custom's (www.custompharm.com) new pharmaceutical
contract manufacturing facility currently being built near Brighton, in the
south of England. This follows the initial Letter of Intent announcement on 9
November 2004.



Internal modification and upgrading of the existing building started in December
2004 and is expected to be completed in approximately three months. The film
casting line, purchased from Valence Technology BV in August 2004, is being
refurbished and will then be delivered and installed along with the other
relevant equipment. The facility and equipment is specified to the latest EC
and US FDA pharmaceutical standards.



The production of BioProgress pharmaceutical grade films in the new plant for
its SOLULEAVESTM, WAFERTABTM and FOAMBURSTTM technologies, as well as films
required for the SWOLLOTM, TABWRAPTM and NROBETM technologies is planned to be
in full production by August 2005.



Nigel Richardson, Chairman of Custom Pharmaceuticals Limited, said: "The more we
have worked with the team at BioProgress, the more excited we have become by the
potential of their innovative technology. We are an established and experienced
medicine manufacturer and our technical team have already spent time in the
BioProgress Tampa film facility, so we are confident we have all the resources,
expertise and qualified personnel to operate the new pharmaceutical film line to
the highest international standards. The BioProgress LOCUM business model makes
sense for all concerned and we are looking forward to a long and fruitful
relationship with BioProgress."